
|Videos|September 9, 2022
Use of PARP Inhibitors in Breast Cancer: Implications for Pharmacy Practice
About 1 in 8 women in the United States will develop breast cancer in their lifetime. Overall mortality for breast cancer has decreased over the years with the addition of complex treatment, such as PARP inhibitors. The webcast discusses this class of medications and see how they fit into the treatment paradigm for breast cancer.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
3
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
4
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
5












































































































































































































